Detalhe da pesquisa
1.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Nature
; 592(7854): 450-456, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33762733
2.
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
J Hepatol
; 80(3): 431-442, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37972660
3.
The Hammersmith Score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden.
Chemotherapy
; 2024 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38679017
4.
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Lancet Oncol
; 24(12): 1411-1422, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37951222
5.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
Hepatology
; 76(4): 1000-1012, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35313048
6.
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study.
Liver Int
; 43(3): 695-707, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36577703
7.
PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma.
Future Oncol
; 19(7): 499-507, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37097715
8.
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
Cancer
; 128(16): 3067-3079, 2022 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35727053
9.
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
J Hepatol
; 77(2): 397-409, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35367533
10.
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
Liver Int
; 42(11): 2538-2547, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35986902
11.
New Frontiers in the Medical Therapy of Hepatocellular Carcinoma.
Chemotherapy
; 67(3): 164-172, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34999584
12.
The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together.
Curr Opin Oncol
; 33(4): 386-394, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33867478
13.
The price and value of therapeutic synergy in liver cancer.
Lancet
; 402(10408): 1108-1110, 2023 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37499669
14.
Dissecting the Tumor Microenvironment to Predict Immunotherapy Response in Hepatocellular Cancer.
Gastroenterology
; 163(6): 1712-1713, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35964689
17.
Preliminary report on endoscopic pilonidal sinus treatment in children: results of a multicentric series.
Pediatr Surg Int
; 34(6): 687-692, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29675752
18.
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma.
Lancet Oncol
; 23(10): e441, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36174622
19.
COVID-19 and liver cancer clinical trials: Not everything is lost.
Liver Int
; 40(7): 1541-1544, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32433799
20.
The long and winding road: Adjuvant therapy for early-stage hepatocellular carcinoma.
Med
; 5(1): 7-9, 2024 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38218177